Top-News
Pharmazeutika Schweden

Camurus AB News

Aktie
WKN:  A2ABG7 ISIN:  SE0007692850 US-Symbol:  CAMRF
45,44 €
+2,90 €
+6,82%
14:38:15 Uhr
Handeln Depot/Watchlist
Aktienanzahl *
55,62 Mio.
Marktkapitalisierung *
2,37 Mrd. €
Streubesitz
-
Index-Zugehörigkeit
-
IR-Website
zur Website
*Stand: 19.01.2024

Camurus AB News

15.07.22 - PLX
Camurus Q2 Net Income SEK 8 Million
(PLX AI) – Camurus Q2 revenue SEK 227 million. • Q2 EBIT SEK 7 million
12.05.22 - PLX
Camurus Q1 Revenue SEK 220 Million
(PLX AI) – Camurus Q1 EBIT SEK 5 million.
16.02.22 - PLX
Camurus Q4 Revenue SEK 183 Million vs. Estimate SEK 177 Million
(PLX AI) – Camurus Q4 EBIT SEK -18 million vs. estimate SEK -22 million.
04.11.21 - PLX
Camurus Q3 Net Income SEK -6 Million
(PLX AI) – Camurus Q3 revenue SEK 154 million. • Q3 EBIT SEK -6 million
13.10.21 - PLX
Camurus Names Garay Alonso as New CFO
(PLX AI) – Camurus appoints Jon U. Garay Alonso as Chief Financial Officer from Feb. 1. • He is currently Finance Director, Europe at Baxter International
16.09.21 - PLX
Camurus Says FDA Grants Orphan Drug Designation in the US for CAM2029
(PLX AI) – Camurus says FDA grants Orphan Drug Designation in the US for CAM2029 for the treatment of polycystic liver disease. • Polycystic liver disease (PLD) is a rare, genetic, ...
15.09.21 - PLX
Camurus CFO Eva Pinotti-Lindqvist Leaves Company
(PLX AI) – Camurus Chief Financial Officer (CFO) Eva Pinotti-​Lindqvist will leave the company. • She will continue until a successor is recruited
15.07.21 - PLX
Camurus Q2 Net Income SEK -48 Million
(PLX AI) – Camurus Q2 revenue SEK 138 million vs. estimate SEK 142 million. • Q2 EBIT SEK -60 million vs. estimate SEK -28 million
26.06.21 - PR Newswire
Camurus announces PDUFA date for Brixadi for the treatment of opioid use disorder in the US
Camurus announces PDUFA date for Brixadi for the treatment of opioid use disorder in the US PR Newswire
26.06.21 - PR Newswire
Camurus announces PDUFA date for Brixadi for the treatment of opioid use disorder in the US
Camurus announces PDUFA date for Brixadi for the treatment of opioid use disorder in the US New PDUFA action date for Brixadi set for 15 December 2021 PR Newswire
15.06.21 - PR Newswire
Camurus announces Braeburn resubmits New Drug Application for Brixadi™ in the US
Camurus announces Braeburn resubmits New Drug Application for Brixadi™ in the US PR Newswire
15.06.21 - PR Newswire
Camurus announces Braeburn resubmits New Drug Application for Brixadi™ in the US
Camurus announces Braeburn resubmits New Drug Application for Brixadi™ in the US PR Newswire
10.05.21 - PR Newswire
Camurus announces publication showing superior patient treatment satisfaction with Buvidal® weekly and monthly depot injections in opioid dependence
Camurus announces publication showing superior patient treatment satisfaction with Buvidal® weekly and monthly depot injections in opioid dependence PR Newswire
10.05.21 - PR Newswire
Camurus announces publication showing superior patient treatment satisfaction with Buvidal® weekly and monthly depot injections in opioid dependence
Camurus announces publication showing superior patient treatment satisfaction with Buvidal® weekly and monthly depot injections in opioid dependence - Randomized, controlled ...
03.05.21 - PR Newswire
The Australian TGA approves key label updates to Buvidal® for treatment of opioid dependence
The Australian TGA approves key label updates to Buvidal® for treatment of opioid dependence PR Newswire
03.05.21 - PR Newswire
The Australian TGA approves key label updates to Buvidal® for treatment of opioid dependence
The Australian TGA approves key label updates to Buvidal® for treatment of opioid dependence PR Newswire
26.03.21 - PR Newswire
Camurus receives positive CHMP opinion for Buvidal 160mg monthly dose for the treatment of opioid dependence
Camurus receives positive CHMP opinion for Buvidal 160mg monthly dose for the treatment of opioid dependence PR Newswire
26.03.21 - PR Newswire
Camurus receives positive CHMP opinion for Buvidal 160mg monthly dose for the treatment of opioid dependence
Camurus receives positive CHMP opinion for Buvidal 160mg monthly dose for the treatment of opioid dependence PR Newswire
18.12.20 - PR Newswire
Swissmedic approves Buvidal for the treatment of opioid dependence
Swissmedic approves Buvidal for the treatment of opioid dependence PR Newswire
18.12.20 - PR Newswire
Swissmedic approves Buvidal for the treatment of opioid dependence
Swissmedic approves Buvidal for the treatment of opioid dependence PR Newswire

Newssuche

Videos

newspaper
07.05.24 +3,75%
Technical Trading: DAX Long kurzfristig
DAX Long Typ: Turbo Open End WKN: NG8K9X Hebel: 26 Laufzeit: OpenEnd Einstieg: Market ... Mehr »